Results for tag: "Parathyroid Hormone"

The Parathyroid Hormone (PTH) market is a specialized segment within the biotechnology industry focused on the development, production, and commercialization of therapies that utilize or modify the parathyroid hormone. These therapies aim to treat conditions arising from the imbalance of calcium and phosphate in the body, such as osteoporosis and hypoparathyroidism. Biotechnological advances, including recombinant DNA technology, have allowed for the synthesis of the active form of PTH or its analogs for therapeutic use. Extended knowledge of the hormone's role in bone metabolism has spurred further research and innovation. Companies in this space may engage in various stages of drug development, including discovery, preclinical testing, and clinical trials. The market is subject to stringent regulatory environments, with products often requiring approval from entities like the FDA or EMA. Patents play an essential role in protecting investments in this field, resulting in competitive dynamics that can influence market growth and accessibility of new treatments. Major players in the Parathyroid Hormone market include Eli Lilly and Company, which markets a synthetic PTH product for osteoporosis treatment, and Entera Bio Ltd., a company focusing on oral PTH formulations. Amgen Inc. also has a presence through its biologic therapies derived from PTH analogs. Additionally, Shire (now part of Takeda Pharmaceutical Company) has contributed treatments for hypoparathyroidism. Other notable companies involved in the PTH market are Ascendis Pharma, Show Less Read more